Pre-treatment genomic-based cancer screening involves analyzing the genetic makeup of a patient’s tumor before starting treatment. This approach identifies specific mutations and biomarkers that can guide the selection of targeted therapies, improve treatment outcomes, and minimize adverse effects. It is a key component of precision oncology.